Alvotech (ALVO) Competitors $8.07 +0.02 (+0.25%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$8.07 0.00 (0.00%) As of 08/29/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALVO vs. BBIO, ELAN, VRNA, ROIV, GRFS, RVMD, RYTM, LEGN, RGC, and RNAShould you be buying Alvotech stock or one of its competitors? The main competitors of Alvotech include BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Grifols (GRFS), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), Legend Biotech (LEGN), Regencell Bioscience (RGC), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry. Alvotech vs. Its Competitors BridgeBio Pharma Elanco Animal Health Verona Pharma PLC American Depositary Share Roivant Sciences Grifols Revolution Medicines Rhythm Pharmaceuticals Legend Biotech Regencell Bioscience Avidity Biosciences BridgeBio Pharma (NASDAQ:BBIO) and Alvotech (NASDAQ:ALVO) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation. Which has stronger earnings & valuation, BBIO or ALVO? Alvotech has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBridgeBio Pharma$235.81M41.96-$535.76M-$4.09-12.66Alvotech$491.98M4.95-$231.86M$0.2335.09 Do analysts recommend BBIO or ALVO? BridgeBio Pharma currently has a consensus price target of $62.18, indicating a potential upside of 20.12%. Alvotech has a consensus price target of $14.00, indicating a potential upside of 73.48%. Given Alvotech's higher probable upside, analysts clearly believe Alvotech is more favorable than BridgeBio Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BridgeBio Pharma 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 3.00Alvotech 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders and institutionals believe in BBIO or ALVO? 99.8% of BridgeBio Pharma shares are held by institutional investors. 18.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media favor BBIO or ALVO? In the previous week, BridgeBio Pharma had 10 more articles in the media than Alvotech. MarketBeat recorded 14 mentions for BridgeBio Pharma and 4 mentions for Alvotech. Alvotech's average media sentiment score of 1.33 beat BridgeBio Pharma's score of 1.14 indicating that Alvotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 7 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alvotech 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is BBIO or ALVO more profitable? Alvotech has a net margin of 11.26% compared to BridgeBio Pharma's net margin of -329.25%. BridgeBio Pharma's return on equity of 0.00% beat Alvotech's return on equity.Company Net Margins Return on Equity Return on Assets BridgeBio Pharma-329.25% N/A -85.69% Alvotech 11.26%-38.36%9.28% Which has more risk & volatility, BBIO or ALVO? BridgeBio Pharma has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Comparatively, Alvotech has a beta of 0.1, suggesting that its stock price is 90% less volatile than the S&P 500. SummaryBridgeBio Pharma and Alvotech tied by winning 8 of the 16 factors compared between the two stocks. Get Alvotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALVO vs. The Competition Export to ExcelMetricAlvotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.43B$3.08B$5.69B$9.74BDividend YieldN/A2.28%6.66%4.48%P/E Ratio35.0920.9283.1926.59Price / Sales4.95352.35515.16159.07Price / CashN/A43.5325.6628.92Price / Book-5.899.7811.766.08Net Income-$231.86M-$54.01M$3.27B$265.93M7 Day Performance-3.00%0.10%1.13%0.36%1 Month Performance-8.19%8.52%8.30%5.58%1 Year Performance-30.91%7.03%62.26%19.67% Alvotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALVOAlvotech3.4701 of 5 stars$8.07+0.2%$14.00+73.5%-30.9%$2.43B$491.98M35.094Positive NewsBBIOBridgeBio Pharma4.1726 of 5 stars$47.29-3.6%$61.35+29.7%+85.9%$9.38B$235.81M-11.56400Positive NewsAnalyst ForecastELANElanco Animal Health2.7583 of 5 stars$17.80-0.6%$17.33-2.6%+18.8%$8.90B$4.48B20.709,000Positive NewsVRNAVerona Pharma PLC American Depositary Share2.2524 of 5 stars$105.62+0.1%$109.00+3.2%+285.4%$8.64B$221.67M-106.6930Positive NewsROIVRoivant Sciences3.1603 of 5 stars$11.64-2.3%$16.50+41.8%-2.5%$8.14B$29.05M-16.63860News CoveragePositive NewsGRFSGrifols3.5394 of 5 stars$9.82-3.3%$10.30+4.9%+6.7%$6.99B$7.81B8.3923,822News CoveragePositive NewsRVMDRevolution Medicines4.3445 of 5 stars$35.67-3.6%$69.92+96.0%-10.9%$6.92BN/A-7.93250News CoveragePositive NewsRYTMRhythm Pharmaceuticals3.4549 of 5 stars$99.20-3.9%$101.57+2.4%+118.1%$6.86B$130.13M-32.96140Positive NewsLEGNLegend Biotech3.6486 of 5 stars$34.60-2.7%$73.00+111.0%-39.7%$6.53B$627.24M-39.322,609Analyst RevisionRGCRegencell Bioscience0.1186 of 5 stars$12.28-4.1%N/AN/A$6.33BN/A0.0010Gap DownRNAAvidity Biosciences3.0542 of 5 stars$45.27-2.3%$67.00+48.0%+5.9%$5.96B$10.90M-12.72190Positive NewsInsider Trade Related Companies and Tools Related Companies BBIO Competitors ELAN Competitors VRNA Competitors ROIV Competitors GRFS Competitors RVMD Competitors RYTM Competitors LEGN Competitors RGC Competitors RNA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALVO) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersNew Banking Law #1582 Could Unlock $21 Trillion for AmericansDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alvotech Please log in to your account or sign up in order to add this asset to your watchlist. Share Alvotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALVO Stock Alerts